Brief: FDA Approves Revumenib For Relapsed Or Refractory Acute Myeloid Leukemia With A Susceptible NPM1 Mutation

Syndax Pharmaceuticals

24/10/2025 18:19

Oct 24 (Reuters) - FDA:

FDA APPROVES REVUMENIB FOR RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WITH A SUSCEPTIBLE NPM1 MUTATION

FDA : APPROVED REVUMENIB, FOR RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WITH A SUSCEPTIBLE  NPM1 MUTATION IN PATIENTS 1 YEAR AND OLDER

Source text: [ID:]

Further company coverage: SNDX.O

 ((Reuters.Briefs@thomsonreuters.com;))